#USA #San Diego #Cizzle Bio #Bill Behnke #Ci4CC Summit

Cizzle Bio's Commitment to Cancer Detection

On May 8-9, 2026, Bill Behnke, the CEO of Cizzle Bio, Inc., participated as a panelist at the City of Hope's 25th Cancer Center Informatics Society (Ci4CC) Summit in San Diego. This summit brought together prominent figures from the fields of translational science, oncology innovation, and biotechnology commercialization to explore vital ways of expediting the development of advanced cancer technologies. The panel discussion, titled "Commercialization of Cancer Therapies Bench to Bedside Drug Development Pipeline," featured esteemed experts including Dr. Linda Malkas, the dean of Translational Science and External Affairs at City of Hope, and other leaders in oncology pharmaceuticals.

Cizzle Bio, known for its innovative biomarker blood tests for early lung and gastric cancer detection, is committed to advancing cancer diagnostics. During the summit, Bill Behnke emphasized the importance of integrating innovative diagnostics with real-world clinical data and collaborations in order to enhance early cancer detection and patient outcomes. "As oncology progresses towards more personalized and data-driven care, it's crucial that we convert scientific innovations into tools that are clinically accessible," said Behnke. His remarks highlighted the collaborative efforts necessary to usher significant innovations from the laboratory to patients' bedsides.

One of Cizzle Bio’s key advancements, the CIZ1B biomarker blood test, is designed to identify lung cancer early through the detection of a tumor-associated protein variant associated with early-stage disease. Developed from extensive research at the University of York, this minimally invasive test boasts an impressive 95% sensitivity for Stage I lung cancer and 96% negative predictive value (NPV). Unlike multi-cancer early detection tests which rely on circulating tumor DNA – often difficult to trace in early-stage cases – the CIZ1B test’s strategy is built upon recognizing a stable and relatively abundant tumor marker linked directly to lung cancer biology.

Furthermore, Behnke announced the upcoming launch of DEX-G2, another breakthrough in cancer diagnostics aimed at early gastric cancer detection. This novel blood test uses an artificial intelligence-driven exosomal microRNA signature developed at City of Hope and validated through the multicenter DESTINEX clinical study which was prominently featured in JAMA Surgery. The DEX-G2 test displayed 95% sensitivity in identifying early gastric cancer and effectively differentiating gastric cancer patients from non-cancer individuals.

Recognizing the alarming statistic that lung and gastric cancers together account for over 7,500 global deaths each day, Cizzle Bio is dedicated to providing accessible and reliable detection methods. The company's mission is clear: to empower patients, equip healthcare providers, and improve overall outcomes through groundbreaking innovations in cancer diagnostics.

Cizzle Bio is based in Texas and holds exclusive licensing rights for the CIZ1B test in the USA, Canada, and the Caribbean, along with a worldwide exclusive license for the DEX-G2 test. By commercializing these advanced tests within U.S. healthcare settings, Cizzle Bio aims to play a pivotal role in transforming cancer diagnostics by making early detection more attainable for everyone.

In summary, Behnke’s participation at the Ci4CC Summit symbolizes a paradigm shift in the landscape of cancer care. By engaging with industry leaders, Cizzle Bio is stepping up to advance not just the science of cancer detection, but also the importance of collaboration among those involved in oncology, thus ensuring that patients have access to the best possible diagnostic tools at the earliest stages of their illness.